Your browser doesn't support javascript.
loading
FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation.
Yan, Chaojun; Gao, Ronghui; Gao, Chuan; Hong, Kai; Cheng, Meng; Liu, Xiaojing; Zhang, Qing; Zhang, Jing.
Afiliação
  • Yan C; Department of Thyroid and Breast Surgery, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
  • Gao R; Department of Thyroid and Breast Surgery, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
  • Gao C; Department of Thyroid and Breast Surgery, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
  • Hong K; Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cheng M; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
  • Liu X; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, United States.
  • Zhang Q; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Zhang J; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Front Oncol ; 13: 1105117, 2023.
Article em En | MEDLINE | ID: mdl-37207154

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China